Neratinib (Nerlynx), an irreversible inhibitor of Her1, Her2, and Her4, which improves patient survival by 2-year when given to women with Her2-positive breast cancer after chemotherapy and adjuvant trastuzumab therapy39. This evidence concerns the gene ERBB2 and breast carcinoma.